Scramble to acquire Paras Pharma - Hindustan Times
close_game
close_game

Scramble to acquire Paras Pharma

Hindustan Times | BySachin Kumar, Mumbai
Sep 15, 2010 11:35 PM IST

The deal to acquire Paras Pharmaceuticals, which owns brands such as Moov, D’Cold, Livon, is stuck on the pricing front as leading pharma majors like Dabur, Piramal Healthcare, Emami Glaxo, Marico, Sanofi-Aventis and Abbott scramble to secure the R500-crore Ahmedabad based company.

The deal to acquire Paras Pharmaceuticals, which owns brands such as Moov, D’Cold, Livon, is stuck on the pricing front as leading pharma majors like Dabur, Piramal Healthcare, Emami Glaxo, Marico, Sanofi-Aventis and Abbott scramble to secure the R500-crore Ahmedabad based company.

HT Image
HT Image

"Paras Pharma is asking for a valuation of around R3,500 to R4,000 crore, which is very high," says a senior official of the company, which is in the race to acquire Paras. "High valuation is the reason behind the delay in the deal," he adds.

Hindustan Times - your fastest source for breaking news! Read now.

Paras is well aware that its product portfolio is tempting for the suitors — which is the main reason behind high valuation, say industry sources. In Over the Counter (OTC) healthcare segment Paras has brands such as Krack, D’Cold, Moov and Livon, Setwet and Borosoft in the personal care segment.

Owning these brands would give a running start in the R8000-crore domestic OTC market. "Paras Pharmaceuticals has brands which are well established in the market," says Ajit Mahadevan, partner, life sciences practice, Ernst & Young. "Branding is a time and money consuming process and acquiring established brands saves time and money."

Piramal Healthcare, Dabur, and Emami already have presence in OTCs and buying Paras Pharma would enhance their portfolio. For multinational like Sanofi-Aventis and Abott, it is a shortcut into the lucrative OTC market.

Another reason behind the scramble for Paras is the lack of similar players up for grabs. "There are very few players like Paras Pharmaceuticals in Indian OTC sector which can be acquired," says an independent pharma consultant.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On